Skip to content
Human Myeloid Phenotyping (27-Color) Flow Cytometry Panel
A 27-color panel phenotyping human myeloid cells, enabling detailed characterization of monocytes, macrophages, and dendritic cell subsets.
Human Myeloid Panel 27 color
Myeloid and dendritic cell populations with expression markers.
| Population / Marker | Definition |
|---|---|
| Core gating | |
| Live Leukocytes | ZombieNIR-CD45+ |
| Lymphocytes vs Monocytes / Granulocytes | SSC vs FSC |
| T cells vs B cells vs Non-B non-T | CD45+SSCloCD3 vs CD19 |
| NK and dendritic cells | |
| NK cells | CD3-CD19-CD56+CD14-HLA-DR- |
| Dendritic cells (DC) | CD3-CD19-CD56-CD14-HLA-DR+ |
| pDC | CD3-CD19-CD56-CD14-HLA-DR+CD11c-CD123+ |
| CD11c+ DC | CD3-CD19-CD56-CD14-HLA-DR+CD11c+CD123- |
| CD11c+ CD16+ DC | CD3-CD19-CD56-CD14-HLA-DR+CD11c+CD123-CD16Hi |
| cDC1 | CD3-CD19-CD56-CD14-HLA-DR+CD11c+CD123-CD16LoCD141+ |
| cDC2 | CD3-CD19-CD56-CD14-HLA-DR+CD11c+CD123-CD16LoCD1c+ CD141- |
| Expression level markers | |
| CD38 | Activation of DC and monocytes |
| CD64 | Inflammation / origin (monocyte-derived DC) |
| CD172a/b | Extra marker for cDC2 / inflammation |
| CD85k | Suppression / tolerance |
| CD15 | Granulocytes and G-Myeloid-Derived Suppressor Cells |
| CD32 | Fc-gamma receptor |
| CD272 (BTLA) | Immune suppression / dampening |
| CX3CR1 | Inflammation / maturation |
| CD163 | M2-like macrophages (immune suppression) |
| CD86 | Upregulated with activation of DC and monocytes |
| CD26 | Cancer Stem Cells |
| CD40 | Th1 (high) or Tolerance (low) DCs |
The Human Myeloid Phenotyping (27-Color) Panel is a pre-optimized flow cytometry panel designed for deep characterization of human myeloid cell subsets. This panel enables detailed profiling of monocytes, macrophages, dendritic cell populations, granulocytic lineages, and other innate immune cells in human peripheral blood and other tissue-derived samples. By integrating a broad set of lineage, activation, and functional markers into a single, optimized assay, the panel supports high-resolution immunophenotyping with minimal setup time.
Key Features & Benefits
Pre-optimized
27-color design minimizes panel development and optimization burden
Comprehensive Myeloid Profiling
Including classical, intermediate, and non-classical monocytes, macrophages, granulocytes, and dendritic cells.
Key Markers
Inclusion of key functional and activation markers enhances identification of myeloid states.
Simultaneous Analysis
Resolution of multiple innate cell subsets in one assay.
Intentional Design
Designed for use with high-parameter cytometry platforms and spectral flow cytometers
Target Immune Cell Populations
This panel resolves the major myeloid lineages in human samples, including classical, intermediate, and non-classical monocytes, various macrophage subsets, conventional dendritic cells, plasmacytoid dendritic cells, granulocytes (such as neutrophils and eosinophils), and other innate cells. By combining lineage markers with functional and activation indicators, researchers can dissect the complexity of the innate immune compartment with high specificity and reproducibility in peripheral blood and other sources like bone marrow or tissue digests.
Scatter, Viability, and Intro T Cell Gating
Human PBMCs from a healthy donor stained with the Human Myeloid Phenotyping (27c) panel. Samples were acquired on a 5-laser (UV/V/B/YG/R) Cytek® Aurora using manufacturer recommended standard instrument settings.
Recommended Application
The Human Myeloid Phenotyping Panel is highly useful for immuno-oncology. This panel supports characterization of tumor-associated macrophages and myeloid-derived suppressor cells to help understand their roles in tumor progression and therapy response.
The panel also facilitates translational research into chronic inflammatory conditions, autoimmune disease, and systemic immune perturbations by providing a detailed snapshot of myeloid subset distribution and functional state. Longitudinal and cohort studies benefit from its standardized design, enabling consistent monitoring of innate immune dynamics over time.